Corvus Pharmaceuticals, Inc. (CRVS)
Develops experimental cancer and immune disease drugs targeting specific immune cell proteins.
$13.31+0.03%Healthcare
StockGlow Score
Leaning Bullish
BearishBullish
1 year ago+224.6%
The outlook
CRVS trades at $13.31, positioned above both its 50- and 200-day moving averages. The stock sits in the lower half of its 52-week range. Analyst consensus targets average roughly 150% above the current price, though coverage details aren't specified here.
What’s behind the score
Price trendAbove its 50- & 200-day averages
52-week range41% of the way from its 52-week low to high
Price targetAvg target +150% vs current price
Analyst price target
~12-month · 6 analysts$33.33average target+150.4% vs now
Now $13.31
Low $27.00High $42.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$1.12B
52-wk high
$26.95
52-wk low
$3.96
50-day avg
$13.20
200-day avg
$12.84
Trailing P/E
—